Citadel Advisors’s Cyclo Therapeutics, Inc. Warrant CYTHW Stock Holding History

Citadel Advisors’s Portfolio CYTHW Stock Details CYTHW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-11,693	Closed	-$1.64K	–	15918
2024 Q4	$1.64K	Buy	11,693 +100	+0.9%	+$16	﹤0.01%	14163
2024 Q3	$1.19K	Buy	11,593 +800	+7%	+$108	﹤0.01%	13881
2024 Q2	$2.48K	Sell	10,793 -200	-2%	-$49	﹤0.01%	13682
2024 Q1	$2.64K	Buy	10,993 +20	+0.2%	+$6	﹤0.01%	13987
2023 Q4	$3.29K	Buy	+10,973	New	+$2.83K	﹤0.01%	13610
2023 Q1	–	Sell	-19,460	Closed	-$10.1K	–	15684
2022 Q4	$10.1K	Buy	+19,460	New	+$11.5K	﹤0.01%	13642

Citadel Advisors's CYTHW Position: Q1 2025 in Review

Citadel Advisors sold out of Cyclo Therapeutics, Inc. Warrant (CYTHW) in Q1 2025, closing a stake of 11,693 shares — an estimated $1.64K sold.

Citadel Advisors first reported a position in CYTHW in Q4 2022 and held it in 6 quarters. The position peaked at $10.1K in Q4 2022. 0 funds tracked by Wall St. Rank hold CYTHW as of Q1 2025.

Citadel Advisors reported no remaining Cyclo Therapeutics, Inc. Warrant position as of Q1 2025 after selling out during the quarter.
Citadel Advisors sold 11,693 Cyclo Therapeutics, Inc. Warrant shares in Q1 2025, an estimated $1.64K.
Citadel Advisors first reported a position in Cyclo Therapeutics, Inc. Warrant in Q4 2022 and held it in 6 quarters.
Citadel Advisors's Cyclo Therapeutics, Inc. Warrant position peaked at $10.1K in Q4 2022.
0 funds tracked by Wall St. Rank held Cyclo Therapeutics, Inc. Warrant as of Q1 2025.

Based on Citadel Advisors's 13F filing for Q1 2025, filed 15 May 2025.